In a recent article published by The Conversation, Ian Hamilton, Associate Professor in the Department of Health Sciences at the University of York, argues that global addiction to illicit drugs represents a worldwide threat on par with climate change. Drawing on findings from the United Nations’ latest World Drug Report, Hamilton highlights the increasing severity of drug production, use, and trafficking, along with their widespread environmental and social consequences.
According to the UN report, cocaine production in Latin America has reached unprecedented levels. Meanwhile, North America is witnessing a surge in the use of synthetic drugs like methamphetamine and fentanyl. These trends are fuelled by organized crime groups who exploit global political instability and weak law enforcement to expand drug trafficking operations—often at the cost of human rights and the environment.
Drug production also inflicts direct harm on ecosystems and local communities. For instance, coca cultivation in South America leads to deforestation, while the toxic chemicals used in processing cocaine contaminate soil and water sources. This environmental degradation makes farming difficult for local residents and exacerbates poverty, perpetuating a cycle of inequality and drug-related harm. The cocaine trade is also associated with violence and exploitation throughout its supply chain.
The report reveals that global drug use has increased by 20% over the past decade, with around 300 million people now regularly using illicit substances. Cannabis remains the most widely used drug (228 million users), followed by opioids (60 million) and cocaine (23 million).
Shifts in the global drug supply chain have further complicated the crisis. In Afghanistan, the Taliban’s 2021 return to power led to a ban on opium cultivation, though heroin stockpiles remain. At the same time, potent synthetic opioids like nitazenes are emerging, potentially reshaping markets. Ongoing conflicts in Syria and Ukraine have also created conditions for new drug trafficking routes. Meanwhile, in Central Asia and Eastern Europe, drug trends are shifting from opiates to synthetic stimulants, with Russia at the forefront of this transition. In North America, the opioid crisis persists, and fentanyl—now primarily trafficked through Mexico—is a major contributor, with large seizures of fentanyl pills recorded across the region.
Despite the bleak outlook, Hamilton highlights signs of progress in drug policy. Initiatives like Scotland’s safe drug consumption site in Glasgow and Portugal’s harm-reduction strategies are examples of effective, evidence-based responses. He emphasizes that addressing inequality and creating safe spaces for drug use can lead to more humane and effective global drug policies.
However, the greatest barriers to progress, Hamilton notes, are stigma and ignorance. “Beliefs are notoriously difficult to shift,” he writes. “As with climate change, the most powerful driver of change is personal experience. We know that when a family or community is affected by a drug overdose, their beliefs and perceptions change. But this is not the way any of us should want to see change happen.”
Hamilton’s analysis is a powerful call to confront the global drug crisis with urgency, compassion, and science-based solution such as safe consumption spaces, as well as global drug policies which address inequality.